Company intelligence / Profile preview

Mysthera Therapeutics AG

Ownership: Private
Development stage: Preclinical

Overview

Developing pre-clinical stage, pan-PIM kinase inhibitors to uniquely modulate multi-lineage immune cell functions. PIM kinase inhibition targets effector B and T cells at inflammation sites and inhibits their activation, silencing the cross-talk between these cells and impeding pathogenic TLS formation associated with more erosive disease[1][6].

Therapeutic areas: Immunology
Modalities: Small molecules (oral therapeutics)
Industry: Biotech

Partnerships

In-licensed PIM kinase inhibitors from Inflection Biosciences Ltd[1][2]

Beyond the preview

Go deeper on Mysthera Therapeutics AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mysthera Therapeutics AG.

Explore the full profile